As the December 31 deadline for the removal of CFC albuterol inhalers in the US approaches, a new report by Kalorama Information forecasts big changes in the global $36bn (€26bn) a year respiratory products market.
The impending ban on albuterol inhalers that use chlorofluorocarbon
(CFC) propellants will see branded hydrofluoroalkane (HFA)-based
products completely dominate the US market as, to date, no generic
HFA albuterol has been developed.
Spanish firm Almirall is working on a new chronic obstructive
pulmonary disease (COPD) treatment combined with a hi-tech easy use
inhaler, creating what it hopes will be another competitive product
from its in-house pipeline.
There are lessons to be learned about the importance of rigorous due diligence of pharma contractors, now that Inyx' customers are facing possible supply issues and a scramble to find alternative manufacturers after the firm's collapse.
The US Food and Drug Administration (FDA) has proposed plans to
phase out chlorofluorocarbons (CFCs) in metered dose inhalers that
contain epinephrine, but the decision could spell the end for some
GlaxoSmithKline (GSK) has suffered a blow in the advance of its top
selling pharma drug Advair after US regulators issued a not
approvable letter for an increased strength in the treatment of
chronic obstructive pulmonary disease.
BioWa has announced it is to commence Phase 1 clinical trials
anti-IL-5 receptor monoclonal antibody (Mab), which is being
developed for the treatment of asthma, a respiratory disorder that
is on the rise, particularly in children.
Curalogic, a Danish biotechnology company, has appointed SAFC's
Pharma business segment to provide protein isolation, extraction
and purification services as part of its product development to
treat Allergic Rhinitis.
The world's most prescribed product for chronic obstructive
pulmonary disease (COPD) could soon be formulated with a new
propellant-free device following an observational study on a soft
mist inhaler (SMI) that Boehringer Ingelheim...
Skyepharma has finally found a partner to license and market its
new asthma drug delivery product after over a year of searching and
one big-pharma partnership that went belly up in 2005 - giving the
company new hope of revamping...
Bang & Olufsen Medicom has joined with specialist device
manufacturer Bespak to co-develop and co-market a new single
increment dose counting inhaler for the expanding asthma and COPD
(chronic obstructive pulmonary disease) market.
Bespak is now ramping up manufacturing of Chiesi Farmaceutici's new
dry powder inhaler (DPI), in preparation for clinical trials of the
device in patients with asthma and COPD (chronic obstructive
British drug delivery firm Vectura has inked a deal with Boehringer
Ingelheim to develop a dry powder inhaler (DPI) for a range of
proprietary respiratory products of the German company,
intensifying competition in a burgeoning asthma...
Ranbaxy has announced the purchase of Senetek's Autoinjector rights
and assets for its proprietary disposable autoinjector for
self-administration of parenteral drugs, adding to Ranbaxy's
growing presence in the growing...
UK drug development company SkyePharma, which put itself up for
sale last month, has said that several new bidders have expressed
interest in buying some of its assets as well as acquiring the
entire company for cash.
UK drug delivery company Skyepharma has been forced to raise funds
to carry out trials of its combination drug for asthma and chronic
obstructive pulmonary disease (COPD) after failing to find a
partner for the project.
Germany's Merck KGaA has laid out its plans to take on the market
for generic respiratory medicines, revealing that it is the
previously unnamed company that has licensed UK inhaler company
Innovata's Clickhaler device in...
Cambridge Antibody Technology (CAT) has announced positive results
of its human anti-IL13 monoclonal antibody, to be used as a
potential treatment for severe asthma. The Phase I clinical trial
of CAT-354 represents research towards...
UK pharmaceutical company ML Laboratories has acquired Quadrant
Technologies, a company specialising in drug formulation and
stabilisation, for £46.7 million (€70m), boosting its capabilities
in the development of inhaled medicines,...
According to data presented this week, multiple second-generation
antisense drugs that show potential as new treatments for asthma
could represent the future in treating this disorder that has
soared in worldwide cases, particularly...
Researchers may have found a novel way to fight asthma by targeting
a protein that is centrally involved in the bronchial inflammation
and airway constriction that prompts asthma's hallmark symptoms.
The antibody treatment is...
Isis Pharmaceuticals is developing its first inhaled antisense drug
for the treatment of asthma and related pulmonary diseases. The
drug represents a potentially effective therapy for these diseases
that continue to see cases rising...
Novartis has announced the formation of an alliance between Vectura
Group and Arakis to develop and commercialise AD 237, a novel, long
acting, antimuscarinic agent, for the treatment of chronic
obstructive pulmonary disease (COPD).
Novartis has acquired a global license to a combination drug and
inhaler device for chronic obstructive pulmonary disease (COPD) in
one of the largest deals signed by the UK biotechnology sector,
reports Phil Taylor.
The US Food and Drug Administration's decision to ban the use of
chlorofluorocarbon propellants in albuterol metered-dose inhalers
(MDIs) from the end of 2008 will effectively mean the market will
revert to one of branded rather...
The Food and Drug Administration (FDA) has set the end of 2008 as
its deadline for the complete phase-out of albuterol inhalers using
ozone-depleting chlorofluorocarbons (CFCs) as propellants,
reports Phil Taylor.
Theravance has announced that GlaxoSmithKline (GSK) has exercised
its option to license Theravance's inhaled bifunctional, muscarinic
antagonist/beta2 agonist (MABA) program under the terms of their
2004 agreement. The compounds...